Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 24, 2026
Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026
Company Deals

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Fineline Cube Mar 24, 2026
Company Deals

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Fineline Cube Mar 24, 2026
Company Deals

Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe

Fineline Cube Mar 24, 2026
Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Fineline Cube Mar 24, 2026
Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Fineline Cube Mar 24, 2026
Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen

Fineline Cube Mar 24, 2026
Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026

Distinct Healthcare Holdings Limited, a China‑based private healthcare service provider, released its prospectus this week...

Company

Merck Establishes Chongqing China Branch in Milestone Expansion

Fineline Cube Jan 29, 2026

Merck Sharp & Dohme (MSD, NYSE: MRK), a US‑based biopharmaceutical giant, announced the establishment of a...

Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026

Biogen Inc. (NASDAQ: BIIB) announced that its investigational litifilimab has received Breakthrough Therapy Designation (BTD) from...

Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026

Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 1 drug TQA3605 has met the primary...

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) approved...

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Fineline Cube Jan 28, 2026

Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from its Phase II clinical trial (CT388‑103)...

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026

The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly...

Company Drug

Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia

Fineline Cube Jan 28, 2026

Novartis (NYSE: NVS) announced that Leqvio (inclisiran) has received an additional indication approval from the National...

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026

Apeloa Pharmaceutical Co., Ltd. (SHE: 000739), a China‑based contract development and manufacturing organization (CDMO), announced...

Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Fineline Cube Jan 28, 2026

China’s State Council this week issued the Implementation Regulations of the Drug Administration Law, a...

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Fineline Cube Jan 28, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received National Medical Products Administration (NMPA)...

Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Fineline Cube Jan 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-5346, the centerpiece of a USD 1.97 billion...

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026

IVD Medical Holding Ltd (HKG: 1931), a China‑based in vitro diagnostic specialist, announced the launch...

Company Drug

Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials

Fineline Cube Jan 28, 2026

Betta Pharmaceuticals (SHE: 300558) announced that the National Medical Products Administration (NMPA) has approved the...

Company Drug

Nanjing Leads Biolabs Secures FDA Fast Track for LBL-034 in Multiple Myeloma

Fineline Cube Jan 28, 2026

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that LBL-034, a GPRC5D/CD3 bispecific antibody (BsAb) T‑cell...

Policy / Regulatory

NMPA Suspends Two Indian Pharma APIs Over GMP Violations

Fineline Cube Jan 27, 2026

China’s National Medical Products Administration (NMPA) announced enforcement actions against two India‑based active pharmaceutical ingredient...

Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026

Zhaoke Ophthalmology (HKG: 6622) announced expanded distribution agreements for BRIMOCHOL PF to include Singapore and...

Company Drug

Innovent Biologics Secures FDA Fast Track for IBI3003 Trispecific Antibody in Multiple Myeloma

Fineline Cube Jan 27, 2026

Innovent Biologics, Inc. (HKG: 1801) announced that the U.S. Food and Drug Administration (FDA) has...

Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026

Insilico Medicine (HKG: 3696), a China‑based generative AI‑driven biotech, announced a strategic partnership with Qilu...

Posts pagination

1 … 24 25 26 … 639

Recent updates

  • Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion
  • Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer
  • Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal
  • Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen
  • Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Others

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.